Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics

$ANIK
Medical/Dental Instruments
Health Care
Get the next $ANIK alert in real time by email

WEST BRIDGEWATER, Mass., Oct. 31, 2024 /PRNewswire/ -- Executive management from Primo Medical Group along with others, combined to acquire Arthrosurface, Inc., a leading provider of joint restoration and preservation solutions for active patients, from Anika Therapeutics (NASDAQ:ANIK). Two former Arthrosurface leaders joined the Primo Medical Group executives in this strategic acquisition which ensures that Arthrosurface's position as a leader in orthopedic joint preservation solutions will resume with its portfolio of innovative products and expertise.

Arthrosurface: A Pioneer in Joint Restoration and Preservation

Shane Shankle, who was appointed Arthrosurface's new President said, "As a leader in joint preservation, I'm excited to drive our company's growth plan by delivering products that help patients maintain an active quality of life."   Frank Fedorowicz, Chief Operating and Financial Officer, added, "I'm very happy to be reunited with many of our founding executives to propel Arthrosurface into its next exciting phase."

With a commitment to minimally invasive techniques, Arthrosurface products are designed to restore natural joint function while preserving surrounding bone and tissue. Arthrosurface's product portfolio includes more than 150 different surface implant curvatures for the knee, shoulder, wrist and toe that are designed to treat upper and lower extremity orthopedic conditions caused by trauma, injury and arthritic disease. Andrea Patisteas, Senior Executive Vice President emphasized that "With over two decades of clinical experience with our implants, we're thrilled to continue working with physicians and patients to provide them with options for the treatment of orthopedic conditions."  Steven Tallarida, President and CEO of Primo Medical Group simply commented "It is great to be back!"

Phoenix Brio will be Arthrosurface's parent company, and both will be based in West Bridgewater, Massachusetts. "The acquisition of Arthrosurface aligns with our mission to create and deliver innovative medical solutions that address today's clinical needs. Arthrosurface is a natural fit for us," said Chris LaPlante, CFO at Primo Medical Group.

Customers and distributors of Arthrosurface products should not expect to see any change in service or disruption in product access or availability.

About Primo Medical Group

Primo Medical Group offers the most comprehensive outsourcing solutions for the medical device market, including OEM product distribution services, engineering services, precision component production, finished goods assembly, medical device refurbishment, reusable surgical kit management and complete supply chain management. Established in 1953, Primo Medical Group is a privately held company with five facilities in Massachusetts. Primo Medical Group is an FDA Registered Contract Manufacturer and is compliant with FDA Quality Systems Regulations. Primo Medical Group is also ISO 13485:2016 certified and is a registered manufacturer with the Office of Defense Trade Controls Compliance. Over the past 24 years Primo Medical Group has incubated and co-funded several new technologies including Angiolink Corporation (acquired by Medtronic), Arthrosurface (acquired by Anika Therapeutics), Spirus Medical, Inc. (acquired by Olympus), Saphena Medical Inc. (acquired by a major strategic in 2024), Cardiosolutions, Inc., Trax Surgical, Inc. and Versago Vascular Access.

For media inquiries, please contact:

Andrea Patisteas

781-828-4400

andreap@primomedicalgroup.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/arthrosurface-returns-to-it-roots-following-divestiture-from-anika-therapeutics-302292970.html

SOURCE Primo Medical Group

Get the next $ANIK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Q&A

New
  • What recent acquisition did Primo Medical Group make?

    Primo Medical Group has acquired Arthrosurface, Inc., a provider of joint restoration solutions, from Anika Therapeutics.

  • What is the primary focus and product range of Arthrosurface?

    Arthrosurface focuses on orthopedic joint preservation solutions with a portfolio of over 150 products for treating extremity conditions.

  • What is the name of the parent company for Arthrosurface following the acquisition?

    Arthrosurface will be positioned under Phoenix Brio, which is the new parent company based in West Bridgewater, Massachusetts.

  • Will the acquisition affect existing customers and distributors of Arthrosurface?

    Customers and distributors should expect no changes in service or disruption in access to Arthrosurface products post-acquisition.

  • Who are the key executives mentioned in the acquisition announcement?

    Shane Shankle, Arthrosurface's new President, and Frank Fedorowicz, CFO, expressed excitement about resuming growth and working with founding executives.

Recent Analyst Ratings for
$ANIK

DatePrice TargetRatingAnalyst
4/17/2025$21.00Buy
B. Riley Securities
11/1/2024$37.00 → $25.00Outperform
Barrington Research
8/14/2023$24.00Mkt Perform → Outperform
Barrington Research
3/7/2023Outperform → Mkt Perform
Barrington Research
11/9/2022$31.00Mkt Perform → Outperform
Barrington Research
10/14/2022$26.00Equal-Weight
Stephens
3/9/2022Outperform → Mkt Perform
Barrington Research
3/9/2022Overweight → Equal-Weight
Stephens & Co.
More analyst ratings

$ANIK
Press Releases

Fastest customizable press release news feed in the world

See more
  • Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025

    BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 63463. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.co

    $ANIK
    Medical/Dental Instruments
    Health Care
  • Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BEDFORD, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the Osteoarthritis ("OA") Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced that on April 1, 2025, Anika granted non-statutory stock options ("Options") covering an aggregate of 3,800 shares of common stock at a per share exercise price of $15.03, which equaled the closing price of common stock on the Nasdaq Global Select Market ("Closing Price") on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compe

    $ANIK
    Medical/Dental Instruments
    Health Care
  • Anika Reports Fourth Quarter and Full Year 2024 Financial Results

    Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Strategic Sale of Parcus Medical complete; resources refocused on programs positioned to generate significantly higher returns BEDFORD, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the Osteoarthritis ("OA") Pain Management and Regenerative Solutions space focused on early intervention orthoped

    $ANIK
    Medical/Dental Instruments
    Health Care

$ANIK
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ANIK
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ANIK
SEC Filings

See more

$ANIK
Leadership Updates

Live Leadership Updates

See more
  • Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    $A
    $ANIK
    $AVNT
    $MASI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care
  • Anika Enters into Cooperation Agreement with Caligan Partners

    Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP ("Caligan"). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed to the Company's Board of Directors, effective immediately. Messrs. Capper and Jellison have nearly 50 years of combined experience building value and driving transformative growth at MedTech compa

    $ANIK
    Medical/Dental Instruments
    Health Care
  • Anika Announces CFO Transition

    BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company's Executive Vice President, Chief Financial Officer ("CFO") and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a smooth transition. "We are pleased to welcome Steve to Anika as we focus on accelerating our pivot to profitability," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "Steve

    $ANIK
    $VSEC
    Medical/Dental Instruments
    Health Care
    Military/Government/Technical
    Consumer Discretionary

$ANIK
Financials

Live finance-specific insights

See more
  • Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025

    BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 63463. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.co

    $ANIK
    Medical/Dental Instruments
    Health Care
  • Anika Reports Fourth Quarter and Full Year 2024 Financial Results

    Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Strategic Sale of Parcus Medical complete; resources refocused on programs positioned to generate significantly higher returns BEDFORD, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the Osteoarthritis ("OA") Pain Management and Regenerative Solutions space focused on early intervention orthoped

    $ANIK
    Medical/Dental Instruments
    Health Care
  • Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025

    BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2024 financial results after the close of the market on Wednesday, March 12, 2025 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 89368. A live audio webcast and accompanying presentation materials will be available in the Investor

    $ANIK
    Medical/Dental Instruments
    Health Care

$ANIK
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more